Literature DB >> 7558229

Effects of hypertension and dyslipidemia on the decline in renal function.

M Mänttäri1, E Tiula, T Alikoski, V Manninen.   

Abstract

Experimental evidence suggests that in addition to hypertension, serum lipids might also accelerate the decline in renal function. We tested this hypothesis in 2702 dyslipidemic middle-aged men without renal disease participating in the Helsinki Heart Study, a coronary primary prevention trial. The decline in renal function was estimated from linear regression slopes based on reciprocals of 10 serum creatinine determinations over the study period. Renal function deteriorated 3% on average during the 5-year study, and hypertension accelerated this change. Subjects with an elevated ratio of low- to high-density lipoprotein cholesterol ( > 4.4) had a 20% faster decline than those with a ratio less than 3.2. Both the contribution of the lipoprotein ratio and the protective effect of high-density lipoprotein cholesterol alone remained significant in multiple regression analyses. In the study of joint effects the contribution of lipids was confined to subjects with simultaneous elevation of blood pressure and lipids. The results suggest that in addition to hypertension, blood lipids also modify the decline in renal function.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7558229     DOI: 10.1161/01.hyp.26.4.670

Source DB:  PubMed          Journal:  Hypertension        ISSN: 0194-911X            Impact factor:   10.190


  56 in total

1.  The incidence of low eGFR and proteinuria in a large tertiary referral lipid clinic.

Authors:  Joseph B Davies; Martin A Crook; Anthony S Wierzbicki; David J Goldsmith
Journal:  Int Urol Nephrol       Date:  2010-08-13       Impact factor: 2.370

2.  Association of APOA5 Gene Promoter Region -1131T>C Polymorphism (rs662799) to Plasma Triglyceride Level in Patients with Type 2 Diabetic Nephropathy.

Authors:  Abdolkarim Mahrooz; Mehryar Zargari; Vahid Ansari; Atieh Makhlough; Mohammad-Bagher Hashemi-Sooteh
Journal:  J Clin Diagn Res       Date:  2016-05-01

Review 3.  HMG-CoA reductase inhibitors and the kidney.

Authors:  Vito M Campese; Bassel Hadaya; Josephine Chiu
Journal:  Curr Hypertens Rep       Date:  2005-10       Impact factor: 5.369

4.  End-stage renal disease risk equations for Hong Kong Chinese patients with type 2 diabetes: Hong Kong Diabetes Registry.

Authors:  X L Yang; W Y So; A P S Kong; P Clarke; C S Ho; C W K Lam; M H L Ng; R R Lyu; D D Yin; C C Chow; C S Cockram; P C Y Tong; J C N Chan
Journal:  Diabetologia       Date:  2006-08-30       Impact factor: 10.122

5.  Evidence-based practice guideline for the treatment of CKD.

Authors: 
Journal:  Clin Exp Nephrol       Date:  2009-12       Impact factor: 2.801

Review 6.  Do statins play a role in renoprotection?

Authors:  Masato Kasahara; Takahiko Nakagawa; Hideki Yokoi; Takashige Kuwabara; Shinji Yasuno; Kiyoshi Mori; Masashi Mukoyama; Kenji Ueshima
Journal:  Clin Exp Nephrol       Date:  2014-01-10       Impact factor: 2.801

7.  Prevalence of mild impairment in renal function in a random sample of elders from a biethnic community survey.

Authors:  R D Lindeman; L J Romero; C L Yau; R N Baumgartner; P J Garry
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

8.  Longitudinal lipid trends and adverse outcomes in patients with CKD: a 13-year observational cohort study.

Authors:  Ching-Wei Tsai; Han-Chun Huang; Hsiu-Yin Chiang; Chih-Wei Chung; Shih-Ni Chang; Pei-Lun Chu; Chin-Chi Kuo
Journal:  J Lipid Res       Date:  2019-01-14       Impact factor: 5.922

9.  Progression of kidney disease in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin versus usual care: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT).

Authors:  Mahboob Rahman; Charles Baimbridge; Barry R Davis; Joshua Barzilay; Jan N Basile; Mario A Henriquez; Anne Huml; Nelson Kopyt; Gail T Louis; Sara L Pressel; Clive Rosendorff; Sithiporn Sastrasinh; Carol Stanford
Journal:  Am J Kidney Dis       Date:  2008-08-03       Impact factor: 8.860

10.  Early development of podocyte injury independently of hyperglycemia and elevations in arterial pressure in nondiabetic obese Dahl SS leptin receptor mutant rats.

Authors:  Kasi C McPherson; Lateia Taylor; Ashley C Johnson; Sean P Didion; Aron M Geurts; Michael R Garrett; Jan M Williams
Journal:  Am J Physiol Renal Physiol       Date:  2016-07-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.